X0407 4 2023-05-04 0 0001805387 Cerevel Therapeutics Holdings, Inc. CERE 0001197018 COLES N ANTHONY C/O CEREVEL THERAPEUTICS HOLDINGS, INC. 222 JACOBS STREET, SUITE 200 CAMBRIDGE MA 02141 1 1 0 0 CEO and Chairperson 1 Common Stock 2023-05-04 4 M 0 50000 3.50 A 52704 D Common Stock 2023-05-04 4 S 0 37568 31.3636 D 15136 D Common Stock 2023-05-04 4 S 0 12132 31.7579 D 3004 D Common Stock 2023-05-04 4 S 0 300 32.93 D 2704 D Stock Option (Right to Buy) 3.50 2023-05-04 4 M 0 50000 0.00 D 2028-12-24 Common Stock 50000 2802417 D These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 9, 2022 adopted by the Reporting Person. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.63 - $31.62. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.63 - $32.04. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. 25% of the shares subject to this option vested and became exercisable on November 27, 2019, with remainder vesting in 36 equal monthly installments thereafter. /s/ Mark Bodenrader, as Attorney-in-Fact 2023-05-08